Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.48 |
| ▸ | TNF | P01375 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19235545 | 0.90 | ADORA2B (0.50) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL19235546 | 0.90 | ADORA2B (0.50) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL16529337 | 0.87 | ADORA2B (0.48) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL20577842 | 0.87 | ADORA2B (0.48) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL16469333 | 0.77 | HSP90AA1 (0.35) | SMN1; SMN2POLB | |
| SCHEMBL19255023 | 0.76 | TP53 (0.35) | LMNASMN1; SMN2RXFP1POLB | |
| SCHEMBL19255024 | 0.76 | TP53 (0.35) | LMNASMN1; SMN2RXFP1POLB | |
| SCHEMBL19235540 | 0.75 | TP53 (0.39) | POLB | |
| SCHEMBL19235536 | 0.75 | TP53 (0.39) | POLB | |
| SCHEMBL19255025 | 0.73 | TP53 (0.37) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533985-B2 | Sulfonamide derivative and medicinal use thereof | EA PHARMA CO., LTD. (JP) | 2017-01-03 | — | — | US | disclosed |
| US-9533985-B2 | Sulfonamide derivative and medicinal use thereof | EA PHARMA CO., LTD. (JP) | 2017-01-03 | — | — | US | disclosed |
| EP-2842945-B1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | EA PHARMA CO LTD (JP) | 2016-10-26 | — | — | EP | disclosed |
| EP-2842945-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | AJINOMOTO CO., INC. (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | AJINOMOTO CO., LTD. (JP) | 2015-02-19 | — | — | US | disclosed |
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | AJINOMOTO CO., LTD. (JP) | 2015-02-19 | — | — | US | disclosed |
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | AJINOMOTO CO., LTD. (JP) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | ITGB4, ITGA4, ITGA2 | ADORA2B 1629/4885TNF 4640/4885ACHE 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.